Citigroup analysts reiterated a Neutral rating on Bristol-Myers Squibb Company PFD CONV 2 (OTC:BMYMP) on January 27, 2026.
Bristol-Myers Squibb Company PFD CONV 2 operates in the Healthcare sector. The stock currently trades at $901.01 with a market capitalization of $1815.9B.